(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.82%) $83.16
(-1.16%) $1.619
(-0.43%) $2 337.00
(0.87%) $27.49
(0.55%) $927.20
(-0.16%) $0.933
(-0.14%) $11.01
(-0.24%) $0.798
(0.00%) $92.17
@ $13.37
发出时间: 15 Feb 2024 @ 03:08
回报率: 11.41%
上一信号: Feb 13 - 23:35
上一信号:
回报率: 0.00 %
Live Chart Being Loaded With Signals
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States...
Stats | |
---|---|
今日成交量 | 772 159 |
平均成交量 | 1.34M |
市值 | 1.75B |
EPS | $0 ( 2024-03-20 ) |
下一个收益日期 | ( $0.340 ) 2024-05-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 23.63 |
ATR14 | $0.00800 (0.05%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-08 | Tierney David S | Buy | 25 000 | Common stock, par value $0.001 per share |
2024-04-08 | Tierney David S | Sell | 25 000 | Common stock, par value $0.001 per share |
2024-04-08 | Tierney David S | Buy | 25 000 | Options to purchase common stock |
2024-03-27 | Elsbernd Brian | Sell | 25 000 | Common stock, par value $0.001 per share |
2024-02-15 | Del Carmen Jeffrey | Sell | 10 667 | Restricted Stock Units |
INSIDER POWER |
---|
37.04 |
Last 100 transactions |
Buy: 3 182 900 | Sell: 1 448 545 |
音量 相关性
Catalyst Pharmaceuticals 相关性 - 货币/商品
Catalyst Pharmaceuticals 财务报表
Annual | 2023 |
营收: | $398.20M |
毛利润: | $313.67M (78.77 %) |
EPS: | $0.670 |
FY | 2023 |
营收: | $398.20M |
毛利润: | $313.67M (78.77 %) |
EPS: | $0.670 |
FY | 2022 |
营收: | $214.20M |
毛利润: | $179.81M (83.94 %) |
EPS: | $0.800 |
FY | 2021 |
营收: | $140.83M |
毛利润: | $118.95M (84.46 %) |
EPS: | $0.380 |
Financial Reports:
No articles found.
Catalyst Pharmaceuticals
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。